Erratum to: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock

Erratum to: Intensive Care Med (2008) 34:1935–1947 DOI 10.1007/s00134-008-1266-6

Due to an oversight by the authors, incorrect data appeared in Table 2. The table is reproduced here with the corrected item in bold type.

Table 2.

Serious bleeding rates in clinical trials of drotrecogin alfa (activated)

Study	Placebo n (%)	DAA n (%)	P
PROWESS	17 (2.0)	30 (3.5)	0.06
PROWESS (CNS)	1 (0.1)	2 (0.2)	NS
ADDRESS	28 (2.2)	51 (3.9)	0.01
ADDRESS (Day 0–6)	15 (1.2)	31 (2.4)	0.02
ADDRESS (CNS)	5 (0.4)	6 (0.5)	0.72
RESOLVE	16 (6.8)	16 (6.7)	0.97
RESOLVE (Day 0–6)	8 (3.4)	9 (3.8)	0.83
RESOLVE (CNS)	5 (2.1)	11 (4.6)	0.13
ENHANCE	–	155 (6.5)	–

Day 0–6: any serious bleeding event occurring during the DAA infusion period

CNS central nervous system bleeding